1
|
Pashaei-Asl R, Khodadadi K, Pashaei-Asl F, Haqshenas G, Ahmadian N, Pashaiasl M, Hajihosseini Baghdadabadi R. Legionella Pneumophila and Dendrimers-Mediated Antisense Therapy. Adv Pharm Bull 2017; 7:179-187. [PMID: 28761819 PMCID: PMC5527231 DOI: 10.15171/apb.2017.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2017] [Revised: 04/29/2017] [Accepted: 04/30/2017] [Indexed: 12/13/2022] Open
Abstract
Finding novel and effective antibiotics for treatment of Legionella disease is a challenging field. Treatment with antibiotics usually cures Legionella infection; however, if the resultant disease is not timely recognized and treated properly, it leads to poor prognosis and high case fatality rate. Legionella pneumophila DrrA protein (Defects in Rab1 recruitment protein A)/also known as SidM affects host cell vesicular trafficking through modification of the activity of cellular small guanosine triphosphatase )GTPase( Rab (Ras-related in brain) function which facilitates intracellular bacterial replication within a supporter vacuole. Also, Legionella pneumophila LepA and LepB (Legionella effector protein A and B) proteins suppress host-cell Rab1 protein's function resulting in the cell lysis and release of bacteria that subsequently infect neighbour cells. Legionella readily develops resistant to antibiotics and, therefore, new drugs with different modes of action and therapeutic strategic approaches are urgently required among antimicrobial drug therapies;gene therapy is a novel approach for Legionnaires disease treatment. On the contrary to the conventional treatment approaches that target bacterial proteins, new treatment interventions target DNA (Deoxyribonucleic acid), RNA (Ribonucleic acid) species, and different protein families or macromolecular complexes of these components. The above approaches can overcome the problems in therapy of Legionella infections caused by antibiotics resistance pathogens. Targeting Legionella genes involved in manipulating cellular vesicular trafficking using a dendrimer-mediated antisense therapy is a promising approach to inhibit bacterial replication within the target cells.
Collapse
Affiliation(s)
- Roghiyeh Pashaei-Asl
- Department of Biology, Payame Noor University, Tehran, Iran.,Department of Anatomy, Medical School, Iran University of Medical Science, Tehran, Iran.,Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Khodadad Khodadadi
- Genetic Theme, Murdoch Children's Research Institute, Royal Children's Hospital, The University of Melbourne, Melbourne, Australia
| | - Fatima Pashaei-Asl
- Molecular Biology Laboratory, Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Gholamreza Haqshenas
- Microbiology Department, Biomedical Discovery Institute, Monash University, Melbourne, Australia
| | - Nasser Ahmadian
- Transplantation Center, Department of Curative Affairs, Ministry of Health and Medical Education, Tehran, Iran
| | - Maryam Pashaiasl
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | | |
Collapse
|
2
|
Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol 2004; 76:585-93. [PMID: 15218053 DOI: 10.1189/jlb.0104034] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Synthetic phosphorothioate oligodeoxynucleotides (ODN) bearing unmethylated CpG motifs can mimic the immune-stimulatory effects of bacterial DNA and are recognized by Toll-like receptor 9 (TLR9). Past studies have demonstrated that nucleotide modifications at positions at or near the CpG dinucleotides can severely affect immune modulation. However, the effect of nucleotide modifications to stimulate human leukocytes and the mechanism by which chemically modified CpG ODN induce this stimulation are not well understood. We investigated the effects of CpG deoxyguanosine substitutions on the signaling mediated by human TLR9 transfected into nonresponsive cells. ODN incorporating most of these substitutions stimulated detectable TLR9-dependent signaling, but this was markedly weaker than that induced by an unmodified CpG ODN. One of the most active ODN tested contained deoxyinosine for deoxyguanosine substitutions (CpI ODN), but its relative activity to induce cytokine secretion on mouse cells was much weaker than on human cells. The activity was dependent on TLR9, as splenocytes from mice genetically deficient in TLR9 did not respond to CpI ODN stimulation. It is surprising that CpI ODN were nearly as strong as CpG ODN for induction of human B cell stimulation but were inferior to CpG ODN in their ability to induce T helper cell type 1 effects. These data indicate that certain deoxyguanosine substitutions in CpG dinucleotides are tolerated to stimulate a TLR9-mediated immune response, but this response is insufficient to induce optimal interferon-alpha-mediated effects, which depend on the presence of an unmodified CpG dinucleotide. These studies provide a structure-activity relationship for TLR9 agonist compounds with diverse immune effects.
Collapse
Affiliation(s)
- Jörg Vollmer
- Coley Pharmaceutical, Elisabeth-Selbert-Str. 9, 40764 Langenfeld, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Cho-Chung YS. Antisense protein kinase A RI alpha-induced tumor reversion: portrait of a microarray. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2004; 1697:71-9. [PMID: 15023351 DOI: 10.1016/j.bbapap.2003.11.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2003] [Accepted: 11/12/2003] [Indexed: 10/26/2022]
Abstract
Antisense oligonucleotides can selectively block disease-causing genes due to the specificity of the Watson-Crick base-pairing mechanism of action. A genome-wide view of antisense technology is illustrated via protein kinase A RI alpha antisense. Complementary DNA microarray analysis of the RI alpha antisense-induced expression profile shows the up- and down-regulation of clusters of coordinately expressed genes that define the molecular portrait of a reverted tumor cell phenotype. This global view broadens the horizons of antisense technology; it advances the promise of antisense beyond a single target gene to the whole cell and the whole organism. Along with recent rapid advances in oligonucleotide technologies-including new chemical and biological understanding of more sophisticated nucleic acid drugs-oligonucleotide-based gene silencing offers not only an exquisitely specific genetic tool for exploring basic science but also an exciting possibility for treating and preventing cancer and other diseases.
Collapse
Affiliation(s)
- Yoon S Cho-Chung
- Cellular Biochemistry Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Rockville Pike, Bethesda, MD 20892-1750, USA.
| |
Collapse
|
4
|
Chen Y, McMicken HW. Intracellular production of DNA enzyme by a novel single-stranded DNA expression vector. Gene Ther 2003; 10:1776-80. [PMID: 12939644 DOI: 10.1038/sj.gt.3302068] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A set of single-stranded DNA (ssDNA) expression vectors, which can generate intracellularly any ssDNA or oligodeoxynucleotide (ODN) molecules, have been developed in our laboratory. Studies from our laboratory as well as our collaborators demonstrated that these ssDNA expression vectors are capable of producing: (1) 10-23 DNA enzyme for downregulating c-raf kinase gene expression and (2) triplex-forming oligodeoxynucleotide (TFO) for inducing genomic recombination. We report here the construction of a new version of ssDNA expression vector. A beta-galactosidase (beta-gal) reporter gene was used as a test target so that the alteration of gene expression can be easily measured using beta-gal activity assay. We designed a 10-23 DNA enzyme molecule that specifically cleaves beta-gal mRNA at protein translation starting site (ATG). Using a cell-free RNA cleavage assay, we confirmed that this DNA enzyme molecule could effectively cleave beta-gal RNA. However, a single substitution from T to G in the catalytic domain of this DNA enzyme molecule abolished its RNA cleavage activity. We also constructed an expression vector that can generate DNA enzyme molecules in cells. A549 lung carcinoma cells were cotransfected with both DNA enzyme expression vector and the beta-gal reporter gene. Compared to the cells that were transfected with the mutated DNA enzyme expression vector, significant reduction of beta-gal gene expression (up to 76%) was observed in the cells transfected with DNA enzyme expression vector as indicated by the protein expression level as well as its enzyme activity. These results further suggest that the ssDNA expression vector has potential applications in the study of gene function and target validation.
Collapse
Affiliation(s)
- Y Chen
- CytoGenix, Inc., Houston, TX 77099, USA
| | | |
Collapse
|
5
|
Abstract
Nucleic acid therapies represent a direct genetic approach for cancer treatment. Such an approach takes advantage of mechanisms that activate genes known to confer a growth advantage to neoplastic cells. The ability to block the expression of these genes allows exploration of normal growth regulation. Progress in antisense technology has been rapid, and the traditional antisense inhibition of gene expression is now viewed on a genomic scale. This global view has led to a new vision in antisense technology, the elimination of nonspecific and undesirable side effects, and ultimately, the generation of more effective and less toxic nucleic acid medicines. Several antisense oligonucleotides are in clinical trials, are well tolerated, and are potentially active therapeutically. Antisense oligonucleotides are promising molecular medicines for treating human cancer in the near future.
Collapse
Affiliation(s)
- Yoon S Cho-Chung
- Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, MD 20892-1750, USA.
| |
Collapse
|
6
|
Abstract
A novel expression vector system has been developed that can intracellularly generate any single-stranded DNA (ssDNA) molecule, such as a triplex-forming oligonucleotide (TFO), antisense oligodeoxynucleotide (ODN) and DNA enzyme, by our laboratory at CytoGenix, Inc. 'Proof of concept' studies from our laboratory as well as our collaborators' indicate that this ssDNA expression vector system is capable of producing, intracellularly, antisense ODNs, DNA enzymes or TFOs for the purpose of downregulating gene expression or inducing targeted genome modification. This technology provides new research tools and has potential applications in gene target validation and drug development.
Collapse
Affiliation(s)
- Yin Chen
- CytoGenix, Inc., 9881 S. Wilcrest Drive, Houston, TX 77099, USA.
| |
Collapse
|
7
|
Chen Y. 10th International Conference on gene therapy of cancer: 13 - 15 December 2001, San Diego, CA, USA. Expert Opin Biol Ther 2002; 2:443-5. [PMID: 11955281 DOI: 10.1517/14712598.2.4.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
This annual meeting was organised by R Sobol and A Deisseroth (Sidney Kimmel Cancer Center, San Diego, CA, USA) and K Scanlon (Keck Graduate Institute, Claremont, CA, USA). The meeting covered a wide range of topics in cancer gene therapy and included five sessions. The topics were: (1) Tumour suppressors/apoptosis/antisense-ribozymes/angiogenesis; (2) Vector systems; (3) Therapy sensitisation/'suicide' gene therapy; (4) Haematopoietic gene transfer; and (5) Poster/discussion sessions. The following meeting highlights have focused mainly on the recent progress in antisense/ribozyme-based approaches useful for cancer gene target validation and drug development.
Collapse
Affiliation(s)
- Yin Chen
- CytoGenix, Inc., 9881 S. Wilcrest Drive, Houston, TX 77584, USA.
| |
Collapse
|